A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

B Cell ALLB-Cell LymphomaB-cell Non Hodgkin Lymphoma

Interventions

DRUG

Anakinra

100mg subcutaneous

Trial Locations (2)

Memorial Sloan Kettering Cancer Center, New York

Hackensack Meridian Health (Data collection only), Hackensack

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER